A coordinated control strategy for insulin and glucagon delivery in type 1 diabetes |
| |
Authors: | Pau Herrero Jorge Bondia Nick Oliver Pantelis Georgiou |
| |
Institution: | 1. Centre for Bio-Inspired Technology, Institute of Biomedical Engineering, Imperial College London, London, UK;2. Institut Universitari d’Automàtica i Informàtica Industrial, Universitat Politècnica de València, València, Spain;3. Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK |
| |
Abstract: | Type 1 diabetes is an autoimmune condition characterised by a pancreatic insulin secretion deficit, resulting in high blood glucose concentrations, which can lead to micro- and macrovascular complications. Type 1 diabetes also leads to impaired glucagon production by the pancreatic α-cells, which acts as a counter-regulatory hormone to insulin. A closed-loop system for automatic insulin and glucagon delivery, also referred to as an artificial pancreas, has the potential to reduce the self-management burden of type 1 diabetes and reduce the risk of hypo- and hyperglycemia. To date, bihormonal closed-loop systems for glucagon and insulin delivery have been based on two independent controllers. However, in physiology, the secretion of insulin and glucagon in the body is closely interconnected by paracrine and endocrine associations. In this work, we present a novel biologically-inspired glucose control strategy that accounts for such coordination. An in silico study using an FDA-accepted type 1 simulator was performed to evaluate the proposed coordinated control strategy compared to its non-coordinated counterpart, as well as an insulin-only version of the controller. The proposed coordinated strategy achieves a reduction of hyperglycemia without increasing hypoglycemia, when compared to its non-coordinated counterpart. |
| |
Keywords: | Artificial pancreas diabetes closed-loop control bihormonal control glucose control insulin delivery |
|
|